Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 4Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

Paclitaxel 62Letrozole 55Fulvestrant 55Trastuzumab 50palbociclib 41pembrolizumab 37Cyclophosphamide 37Carboplatin 37Anastrozole 37pertuzumab 35exemestane 25Tamoxifen 24Capecitabine 24ribociclib 23abemaciclib 23Radiotherapy 21Docetaxel 21olaparib 20Doxorubicin 20Magnetic Resonance Spectroscopy 19trastuzumab deruxtecan 17Surveys and Questionnaires 17durvalumab 16Epirubicin 16Specimen Handling 14Exercise 14130-nm albumin-bound paclitaxel 14Taxes 13Alpelisib 13Goserelin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Breast Neoplasms × alovudine × Clear all
NCT01251874 2026-05-22

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
44 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02608216 2025-09-03

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

University of Pennsylvania

Phase 1 Active not recruiting
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡